Healthcare advocacy groups and the pharma industry will be watching for developments this fortnight on the fixed-dose combination medicines (FDCs) controversy. Earlier this month, the Delhi High Court had quashed the Government's ban on 344 FDCs. An FDC combines two or more medicines in one pill or product. And they came under the scanner as the rationale behind the combination was called into question. While some drugs may have a legitimate scientific rationale or may have brought a genuine convenience to the patient, many are a product of mere commercial reasons, say health advocacy representatives.Will the Centre appeal the High Court judgement in the same court, or approach the Supreme Court?
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.